Enovis Corporation
ENOV
Positions held
Your positionsENOV isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Enovis Corporation operates in the medical devices industry, which is expected to grow significantly due to increasing healthcare demands and technological advancements.
- The company's revenue for the latest quarter was $582.782 million, showing a slight decrease of 1% compared to the previous quarter.
- Enovis has a strong recommendation of 'strong buy' with a target mean price of $37.58, indicating potential upside from its current market price.
- The company is facing challenges with a negative profit margin of -47.97%, indicating ongoing financial struggles.
- Enovis reported a net income of -1.19 million in the latest quarter, continuing a trend of losses over the past several quarters.
- The stock has a 'Strong Sell' signal with a score of -15.00, reflecting negative market sentiment and technical indicators.
Fundamentals
| Market cap | $1.01B | Enterprise value | $2.36B | Trailing P/E | — | Forward P/E | 4.85 |
| PEG | 3.45 | Price / book | 0.68 | Beta | 1.48 | Dividend yield | 0.00% |
| Revenue growth | 3.2% | Earnings growth | — | Gross margin | 61.3% | Operating margin | 4.2% |
| Profit margin | -48.0% | ROE | -54.1% | ROA | 1.2% | Debt / equity | 0.93 |
| Current ratio | 1.99 | Free cash flow | $185.94M | Analyst recommendation | strong_buy | Mean target | $37.58 |
| 52w high | $34.28 | 52w low | $16.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $583M | $589M | $576M | $549M | $565M | — |
| Op margin | 3.8% | 1.6% | 8.4% | -1.5% | -2.8% | — |
| Net income | -$1.2M | -$8.8M | -$521M | -$571M | -$36.7M | — |
| Gross margin | 61.6% | 62.0% | 60.7% | 59.9% | 59.3% | — |
| Gross profit | $359M | $365M | $349M | $329M | $335M | — |
| Operating income | $22.3M | $9.2M | $48.3M | -$8.1M | -$16.1M | — |
- Revenue -1% vs prior quarter ($583M vs $589M).
- Gross margin 61.6% (was 62% prior quarter).
- Operating margin expanded to 3.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.2B | $2.1B | $1.7B | $1.6B | — |
| Op margin | -0.8% | -4.9% | -2.8% | -5.8% | — |
| Net income | -$1.2B | -$825M | -$33.3M | -$13.3M | — |
| Gross margin | 59.8% | 56.0% | 58.0% | 55.6% | — |
| Gross profit | $1.3B | $1.2B | $991M | $869M | — |
| Operating income | -$18.9M | -$103M | -$48.4M | -$90.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · 1 of Wall Street’s Favorite Stocks with Solid Fundamentals and 2 We Avoid
2026-10-08 · Enovis to Host Third Quarter 2026 Results Conference Call on November 5th
2026-10-05 · BofA Securities Adjusts Enovis Price Target to $44 From $51, Maintains Buy Rating
2026-10-05 · 3 Small-Cap Stocks We Approach with Caution
2026-09-28 · 1 Oversold Stock Ready to Bounce Back and 2 That Underwhelm
2026-09-22 · Enovis becomes first multi-registry industry sponsor of AAOS Registry Program
2026-09-21 · 2 Russell 2000 Stocks on Our Watchlist and 1 We Brush Off
2026-09-17 · 3 Reasons ENOV is Risky and 1 Stock to Buy Instead
2026-09-14 · Insider at Medical Device Maker Buys More Than 7,500 Shares
2026-09-04 · Q2 Earnings Highlights: Enovis (NYSE:ENOV) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
2026-09-04 · Enovis (ENOV) Stock Fair Value Falls As Analysts Weigh Robotics And Margin Pressure
Price (daily)
Full chart · RSI · MACD · patterns